Current stock page

Stock Analysis

Immunome, Inc. (IMNM) Stock Analysis

Immunome, Inc. (IMNM) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

IMNM Stock Analysis Summary

Immunome, Inc. (IMNM) currently has an AIQ Score of 48/100, indicating a bearish setup. Quality is the strongest factor at 52/100. Momentum is the weakest current factor at 45/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

IMNM at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$18.77
AIQ Score48/100
Overall ViewBearish
Technical Analysis ConsensusSell
Market Cap$2.13B
P/E Ratio (TTM)-7.08
Forward P/E—
EPS (Q3 FY2026)-$0.76
Revenue (Q3 FY2026)$0
Dividend Yield (TTM)0.00%
Beta1.47
Volume951.08K
52-week range$16.11-$30.06
RSI 1446.9
50-Day SMA$20.65
200-Day SMA$22.21
Analyst Price Target$27.00
Next EarningsMar 2, 2027
As of Nov 13, 2026 · Market close

IMNMImmunome, Inc.

Healthcare / Biotechnology

Relative Leader / Watch

Strong Relative Position

BearishEdge 8/10
$18.77+$0.07 (+0.37%)

Latest quote

  • Momentum
    45
  • Value
    —
  • Quality
    52
  • Risk resilience
    47
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

IMNM Stock Analysis Summary

Immunome, Inc. (IMNM) currently has an AIQ Score of 48/100, indicating a bearish setup. Quality is the strongest factor at 52/100. Momentum is the weakest current factor at 45/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bearish

In a bearish regime, IMNM has AIQ Score of 48/100 with Quality base of 52/100 and fading Momentum at 45/100. Wait for component alignment before adding exposure.

Healthcare · 0.37% stock move · IMNM classified in Biotechnology.

Current Evidence

BearishIMNM is in a bearish AIQ regime; Quality is the strongest visible factor at 52/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is IMNM Bullish or Bearish Right Now?

IMNM currently has a bearish overall setup. Quality is the strongest factor at 52/100, while Momentum is weakest at 45/100. The current evidence suggests a bearish setup.

Bull Case
  • - Analyst target implies +43.85% upside from the latest quote.
Bear Case
  • - Momentum is weak at 45/100.
  • - Risk Resilience is weak at 47/100.
  • - Price is -15.50% below its 200-day SMA.
  • - Technical consensus has more sell votes than buy votes (22 vs 15).

Current Consensus

IMNM's Technical Analysis Consensus is currently Sell, with 15 buy, 9 neutral, and 22 sell votes. IMNM's 14-day RSI is 46.9, which places the stock in a neutral momentum range. IMNM's beta is 1.47, indicating greater market sensitivity than the broad market.

Signal Confidence
Moderate agreement

What Changed in IMNM?

The largest recent change in IMNM is Quality moving down by 8.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.

AIQ Score
-2.0
Momentum
+3.0
Quality
-8.0
Risk
-1.0

What Would Change the IMNM Outlook?

The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

IMNM Decision Framework

Public evidence layers, setup checks, and risk context for Immunome, Inc..

Immunome, Inc. (IMNM) Stock Analysis

Immunome, Inc. has an AIQ Score of 48/100 in a Bearish regime. Quality is strongest at 52/100. Beta is 1.47, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextIMNM is in a Bearish AIQ regime with score 48/100.
Signal ConflictThe primary conflict is that quality leads at 52/100 while momentum lags at 45/100.
Factor EvidenceMomentum 45/100 · Quality 52/100 · Risk 47/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthWait

Quality is the strongest factor at 52/100.

TimingFail

Momentum is 45/100 and RSI (14) is 46.9.

Regime fitFail

IMNM is in a Bearish regime at 48/100.

Risk controlFail

Risk factor is 47/100 with beta 1.47 and annual volatility 60.72%.

ConflictPass

Current conflict: quality leads at 52/100 while momentum lags at 45/100.

AIQ Score
48/100
Price
$18.77
Beta
1.47
RSI (14)
46.9

IMNM Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

IMNM Fundamentals

IMNM valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$0
Net income
-$85.78M
Free cash flow
-$61.24M
View full IMNM fundamental analysis

IMNM Technical Analysis

IMNM technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Sell
RSI 14
46.9
Price vs SMA-50
-9.11%
View full IMNM technical analysis

IMNM Stock Catalysts

Track IMNM earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Mar 2, 2027
Analyst target
$27.00
News items
4
View IMNM earnings and stock catalysts

IMNM Dividend Analysis

IMNM dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View IMNM dividend history and analysis

IMNM Financial Data

IMNM revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$0
EPS
-$0.76
Periods
8
View IMNM financials

IMNM Risk Analysis

IMNM volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
1.47
Risk score
47/100
1Y volatility
60.72%
View IMNM risk analysis

IMNM Stock News

IMNM stock news, market tone, recent headlines, and catalyst context.

News items
4
Updated
Nov 15, 2026
Sentiment
—
Read IMNM stock news

IMNM vs Biotechnology Peers

Current peer cohort: IMNM · IMVT · INBX · INSM · INVA. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
IMNM
Current stock
48/100—45/10047/1000.4560.72%Current
IMVT
Immunovant, Inc.
52/100—61/10052/1000.958.62%IMNM vs IMVT
INBX
Inhibrx Biosciences Inc.
40/100—50/10040/1000.4982.28%IMNM vs INBX
INSM
Insmed Incorporated
57/10055/10061/10049/100-0.4863.12%IMNM vs INSM
INVA
Innoviva, Inc.
67/10092/10043/10074/100-0.6425.21%IMNM vs INVA
Pairwise Compare links: IMVT · INBX · INSM · INVAIMNM vs IMVTIMNM vs INBXIMNM vs INSMIMNM vs INVACompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a IMNM stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for IMNM: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-7.08
As of Nov 13, 2026
Revenue growth
—
Gross margin
0.00%
Current debt / equity
0.03
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$0
Quarter net income
-$85.78M
Quarter free cash flow
-$61.24M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bearish
Momentum
Mixed
RSI 14
46.9
MACD
-0.37

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
47/100
Beta
1.47
Annual volatility
60.72%
Max drawdown
-44.78%

IMNM Stock FAQ

What is IMNM stock price today?

Immunome, Inc.'s current stock price is $18.77. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is IMNM bullish or bearish right now?

IMNM's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is IMNM's market cap?

IMNM's market cap is $2.13B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is IMNM's current P/E ratio?

IMNM's current P/E ratio is -7.08 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is IMNM's RSI?

IMNM's 14-day RSI is 46.9 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is IMNM above its 50-day and 200-day moving averages?

IMNM is -9.11% from its 50-day SMA and -15.50% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is IMNM's next earnings date?

IMNM's next earnings date is currently listed as Mar 2, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does IMNM pay a dividend?

IMNM's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.